Products / Onchology y Oncohematology

Fontrax

Dasatinib 50-100 mg

Dasatinib is indicated for the treatment of chronic myelogenous leukemia and Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL).

Therapeutic Action

Antineoplastic

Presentations

Fontrax 50: 60 tablets Fontrax 100: 30 tablets

This pharmaceutical product is gluten free. Suitable for celiacs.
Fontrax Dasatinib 50-100 mg de Laboratorios Richmond
Download Prospect

Legal Notice

Products which continue to have a valid patent protection at present are manufactured in line with the current laws of the Argentine Republic. Please, take into account that our products will only be shipped to countries where the substance and its use are not protected by patents.

Laboratorios Richmond S.A.C.I.F. Argentina © All rights reserved Terms of use